HSPA5 and neoplasm: The authors observed a decrease in tumor volume and weight, in vivo, exclusively through the use of miR-122 from adipose tissue-derived MSC EVs combined with sorafenib [139] for GRP78-siRNA EVs transfected into hepatocellular carcinoma cells, leading to a significant reduction in sorafenib resistance and tumor metastasis formation [140].